-- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) -- STAMFORD, Conn., June 10, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that it is expanding access to its rapid whole genome sequencing (rWGS) services in neonatal intensive care units (NICUs) with leading health systems through a new collaboration with Epic.

--使用Epic进行电子连接以简化卫生系统的访问并改善提供者和患者的旅程的新整合----增加商业足迹并专注于加速新生儿重症监护病房（NICU）rWGS服务的利用----康涅狄格州斯坦福德，2024年6月10日（全球新闻专线）--GeneDx（纳斯达克：WGS），一家通过基因组洞察提供改善健康结果的领导者，今天宣布，它正在通过与Epic的新合作，扩大其在新生儿重症监护病房（NICU）中快速全基因组测序（rWGS）服务的使用范围。

The integration with Epic expands GeneDx’s commercial strategy by connecting directly with health systems that use Epic’s EHR to receive orders and send results. With more than 20 years of experience leading the industry in diagnosing children with rare diseases, including performing more than 80% of clinical exomes in the US today, GeneDx is increasing its focus to a rapidly growing segment of its business.

与Epic的集成通过直接连接使用Epic的EHR接收订单和发送结果的卫生系统，扩展了GeneDx的商业战略。GeneDx在诊断罕见疾病的儿童方面拥有20多年的行业领先经验，包括目前在美国完成了80%以上的临床外显子组，它正将重点放在其业务的快速增长部分。

GeneDx has seen an 80% year over year increase of its rapid testing business, and the payor landscape is rapidly evolving, with 11 states now offering Medicaid coverage and an increasing number of commercial payors adopting coverage policies for this critical testing. Patients will now have rWGS results seamlessly integrated into their single, comprehensive medical record, enabling providers to deliver more comprehensive patient care.

GeneDx的快速测试业务同比增长了80%，付款人的情况正在迅速发展，目前有11个州提供医疗补助，越来越多的商业付款人采用覆盖政策进行这项关键测试。患者现在将rWGS结果无缝集成到他们的单一综合病历中，使提供者能够提供更全面的患者护理。

“Access to rWGS leads to improved patient outcomes by accelerating the timeline between diagnosis and treatment. As GeneDx continues to drive utilization of its whole exome sequencing in the outpatient setting, today’s announcement affirms our commitment to opening up access to our rWGS services for health system partn.

“通过加快诊断和治疗之间的时间线，获得rWGS可以改善患者的预后。随着GeneDx继续推动其全外显子组测序在门诊环境中的应用，今天的公告肯定了我们对为卫生系统partn开放rWGS服务的承诺。